S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Buy THIS stock before Taiwan is attacked (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Buy THIS stock before Taiwan is attacked (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Buy THIS stock before Taiwan is attacked (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Buy THIS stock before Taiwan is attacked (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
NASDAQ:CARA

Cara Therapeutics (CARA) Price Target & Analyst Ratings

$3.40
+0.12 (+3.66%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$3.24
▼
$3.42
50-Day Range
$3.28
▼
$5.49
52-Week Range
$3.24
▼
$12.98
Volume
618,200 shs
Average Volume
614,920 shs
Market Capitalization
$183.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.83
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Cara Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$15.83
365.69% Upside
High Prediction$25.00
Average Prediction$15.83
Low Prediction$4.00
TypeCurrent
5/29/22 to 5/29/23		1 Month Ago
4/29/22 to 4/29/23		3 Months Ago
2/28/22 to 2/28/23		1 Year Ago
5/29/21 to 5/29/22
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$15.83$17.00$25.67$26.80
Predicted Upside365.69% Upside127.98% Upside127.66% Upside115.53% Upside
Get Cara Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.


CARA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CARA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cara Therapeutics Stock vs. The Competition

TypeCara TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside365.69% Upside1,291.79% Upside196.76% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/16/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$6.00 ➝ $4.00-3.61%
5/16/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$20.00 ➝ $15.00+261.45%
4/4/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$22.00+375.16%
3/7/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$29.00 ➝ $25.00+273.69%
3/7/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight$19.00 ➝ $16.00+139.16%
3/7/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight$25.00 ➝ $13.00+29.74%
(Data available from 5/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CARA Price Target - Frequently Asked Questions

What is Cara Therapeutics's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Cara Therapeutics stock is Moderate Buy based on the current 1 sell rating and 5 buy ratings for CARA. The average twelve-month price prediction for Cara Therapeutics is $15.83 with a high price target of $25.00 and a low price target of $4.00. Learn more on CARA's analyst rating history.

Do Wall Street analysts like Cara Therapeutics more than its competitors?

Analysts like Cara Therapeutics more than other Medical companies. The consensus rating for Cara Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how CARA compares to other companies.

Is Cara Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Cara Therapeutics's stock had 1 downgrade by analysts.

Does Cara Therapeutics's stock price have much upside?

According to analysts, Cara Therapeutics's stock has a predicted upside of 134.37% based on their 12-month price targets.

What analysts cover Cara Therapeutics?

Cara Therapeutics has been rated by Bank of America, Canaccord Genuity Group, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, and Piper Sandler in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:CARA) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -